Want to see FTH full AI Analyst Report?
FTH Stock Chart & Stats
$11.42
-$0.03(-5.03%)
At close: 4:00 PM EST
$11.42
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$7.45 - $37.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)38.93K
Market Cap
$826.89M
Enterprise Value-$38.00
Total Cash (Recent Filing)$186.44M
Total Debt (Recent Filing)$592.00K
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 10, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-141.65
Shares Outstanding25,840,425
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.50Price Target Upside385.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-15.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt lowers solvency pressure and preserves financing flexibility while Faeth advances its development pipeline. This balance-sheet support is durable, although it cannot by itself replace the need for revenue or additional capital.
Improving Cash-Flow TrendThe reduced rate of free-cash-flow depletion could extend the company’s operating runway and improve capital efficiency. However, cash generation remains negative, so this is a favorable trend rather than evidence of self-funding operations.
Performance-Based IncentivesTying employee and leadership rewards to demanding long-term performance or transaction outcomes can strengthen retention and shareholder alignment. The plan supports governance incentives, though it does not directly improve the pipeline, revenue, or cash position.
Bears Say
No Revenue And Persistent LossesLack of commercial revenue leaves Faeth dependent on successful clinical development and future financing rather than an established operating model. Persistent losses also reduce visibility into eventual margins, profitability, and the durability of the business.
Ongoing Cash BurnContinued operating cash burn means the company is not self-funding and will likely require external capital if losses persist. This creates enduring execution and financing risk, particularly if development spending remains elevated before commercialization.
Dilution And Financing DependenceThe financing program provides capital access but may dilute existing holders as shares are issued. The large preferred conversion and fluctuating equity levels reinforce the need for outside funding, potentially limiting per-share participation in future success.
Faeth Therapeutics News
FTH FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was $7.45 and its highest was $37.90 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is $826.89M.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.636 by -$0.204.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 25,840,425 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.636. Following the earnings report the stock price went down -6.73%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in FTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faeth Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.50 (385.99% Upside)
$55.50 (385.99% Upside)
Blogger Sentiment
Bullish
FTH Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $187.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
436.62%
Trailing 12-Months
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
FTH Stock 12 Month Forecast
Average Price Target
$55.50
▲(385.99% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Ownership Overview
5.14% Insiders
0.26% Mutual Funds
46.62% Other Institutional Investors
47.92% Public Companies and
Individual Investors